Novartis Statistics

Novartis Statistics and Facts

Novartis AGs


  • Type of Business


  • Establishment Year


  • Headquarters

    Basel, Switzerland

  • CEO and Key People

    Vasant (Vas) Narasimhan (CEO), Shreeram Aradhye (Chief Medical Officer), James (Jay) Bradner (President, Novartis Institutes for BioMedical Research), Karen L. Hale (Chief Legal Officer), Harry Kirsch (Chief Financial Officer), Steffen Lang (President, Operations), and other key peoples.

  • Number of Employees

    ~ 104,323 (2022)

  • Industry

    Pharmaceutical Manufacturing

  • Revenue

    US$51,630 million (2021)

  • Products

    Pharmaceuticals(Cancer, Cardio Metabolic, Cell and Gene Therapy, Immunology and Dermatology, Neuroscience, Ophthalmology, and Respiratory.), Eye Care Products(Surgicals, Vision Care Products, Ophthalmic Pharmaceuticals, and Generic Medicines and Biosimilars.)

  • Brands

    Galvus, Eucreas, Tyzeka / Sebivo, Extavia, Exelon & Exelon Patch, Gilenya, Cibacen, Exforge, Exforge HCT, Diovan, Diovan HCT/Co-Diovan, Ritalin & Ritalin LA, Gleevec/Glivec, Zometa, Jakavi, Femara, Signifor, Focalin & Focalin XR, Stalevo, Trileptal, Tegretol, Afinitor/Votubia, Exjade, and Tasigna.

  • Subsidiaries

    Sandoz, Advanced Accelerator Applications, Novartis Pharma K.K., Novartis Gene Therapies, Medicines Company (The), Hexal AG, Novartis Foundation, Novartis Ireland Limited, Vedere Bio Inc., Novartis India Ltd., Chiron Corporation, and many other subsidiaries.

  • Competitors

    Abbott Laboratories, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Merck, GSK, Pfizer and many other competitors.

  • Website

Novartis Statistics: Novartis AG is changing the way medicine works to make people’s lives better and more fulfilling. As a world-leading medicines company, Novartis uses cutting-edge science and digital technologies in order to create innovative treatments in areas of high medical need. Novartis AG is a holding company that is involved in the development, manufacturing, and marketing of healthcare products. It operates in three segments: Innovative Medicines (Sandoz), Corporate, and Marketing. The Innovative Medicines section is composed of two business units, Novartis Pharmaceuticals, and Novartis Oncology. It focuses on the development, manufacturing, distribution, and sale of patent-pending pharmaceuticals. The Sandoz Segment develops, manufactures, markets, and distributes finished dosage form medicines. It also produces intermediary products which include active pharmaceutical ingredients. The Corporate segment includes central services and group management. The company was founded in Basel on 29 February 1996.

The goal of Novartis is to reimagine medicine and improve the lives of people. Innovative science and technology are used to address some of society’s most complex healthcare problems. They find innovative ways to make these treatments available to as many people as they can. Additionally, they want to reward all those who invest in the company with their money, time, and ideas.

The quest for new medicines has consistently made one of the most prominent companies in the world invest in research. Novartis products have been accessed by more than 1 billion people around the world. They are constantly looking for innovative ways to make it easier to access their most recent treatments. The company employs approximately 104,000 people worldwide, representing more than 140 nationalities.


Albania, Algeria, Angola, Argentina, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Barbados, Belgium, Bosnia, Botswana, Brazil, Bulgaria, Cameroon, Canada, Chile, China, Columbia, Costa Rica, Croatia, Curacao, Cyprus, Dominican Republic, Denmark, Ecuador, Egypt, El Salvatore, Estonia, Finland, Germany, France, Ghana, Guatemala, Greece, Honduras, Iceland, Hungary, India, Iran, Indonesia, Ireland, Italy, Jamaica, Israel, Japan, Kazakhstan, Kenya, Jordan, Kosovo, Latvia, Lebanon, Kuwait, Luxemburg, Malta, Malaysia, Mauritius, Montenegro, Mexico, Namibia, New Zealand,  Netherlands, Nigeria, Oman, Norway, Pakistan, Peru, Panama, Philippines, Portugal, Poland, Qatar, Russia, Romania, Saudi Arabia, Serbia, Senegal, Singapore, Slovenia, Slovakia, South Africa, Sri Lanka, Spain, Sweden, Taiwan, Switzerland, Thailand, Tunisia, Trinidad and Tobago, Turkey, UAE, Ukraine, the US, the UK, Venezuela, Uruguay, Vietnam, Zambia.

Research Disease Areas

The mission is to discover and advance new treatments for severe patient needs. Novartis teams of disease area specialists collaborate across scientific disciplines to advance the mission of improving and prolonging people’s lives, from the initial therapeutic development phase through early clinical trials.

  • The Autoimmunity, Transplantation & Inflammatory Disorder group is currently developing transformative therapies, including small molecules, biotherapeutics, and immunotherapeutics, which target the root causes of disease. This includes modulating the immune system in order to restore health.
  • The Cardiovascular & Metabolic Diseases group works to understand the root causes and develop treatments against them.
  • DAX drives transformational therapies for high-potential emerging indications. The research currently underway focuses on liver and respiratory diseases, as well as non-malignant blood disorders.
  • Immuno-Oncology scientists are working on a variety of immunotherapies for cancer.
  • The Musculoskeletal Diseases research group’s mission is to restore mobility and independence for patients with severe conditions.
  • the neuroscience research team aims to find transformative therapies for neurodegenerative, neurodevelopmental, or psychiatric conditions to dramatically improve patients’ lives.
  • The Oncology group is currently developing a comprehensive portfolio of treatments that target tumors in a specific way and eliminate their defenses.
  • The Ophthalmology Research Team is currently developing a wide range of compounds (small molecules, biologics, gene-based therapies) that will protect and restore your vision.
  • The Novartis Institute for Tropical Diseases, a drug discovery research center, is dedicated to discovering new treatments for neglected tropical diseases. This includes malaria, cryptosporidiosis, Chagas Disease, and human African trypanosomiasis.

Managed Access Programs

Patients suffering from life-threatening conditions or severe diseases sometimes need medical products that aren’t yet available or approved in their country. Novartis Managed Access helps to address this need by making unapproved or investigational treatments available for eligible patients. These programs are described in more detail below.

In some cases, patients may be diagnosed with a serious or potentially life-threatening condition. If this happens, enrollment in a clinical study is impossible. If the local laws allow, the treating doctor can request an investigational/pre-approval product before regulatory approval. Novartis calls such provision of pre-approval and investigational products “Managed Access.”

Novartis’s Oncology Access

Novartis AG Oncology Access is also known as NOA. It is a sustainable access solution that is intended to improve access in countries without a lot of healthcare reimbursement. Novartis’ NOA partnership-based approach allows sharing the cost of medicines with other payers such as charities and government healthcare systems. Patients without insurance who are unable or unwilling to pay the full cost of their medication can also be covered by NOA.

Three models are specifically used in the program:

  • Participation in a shared contribution where the national or provincial governments, as well as other entities, share the costs of treatment;
  • The co-pay is where the patient shares in the costs of treatment.
  • Some products may be donated in full


Goodwill results from the application of the acquisition method to the acquisition of a business. It is the excess of the fair value of consideration transferred to acquire a business over the underlying value of the assets acquired. It is assigned to cash-generating units, which are often represented by reported segments. The goodwill is subject to impairment testing at the level of these CGUs.


Novartis AG Global Revenue

The total revenue of the Swiss pharmaceutical company in 2021 was 51,600 million U.S. Dollars. This is an impressive increase of around 3,000 million U.S. Dollars compared to the previous year.

Novartis AG Revenue, by Segment

Novartis AG earned approximately 42,000 million U.S. dollars from its branded pharmacy business segment in 2021. The company also generated 9,600 million in the same year from Sandoz, its generic drug division.

Novartis AG Expenditure on Research and Development

This statistic shows how much the company spent on research and development between 2004 and 2021. This is the largest pharmaceutical company in the world. They spent approximately 9,500 million U.S. Dollars on research and development in 2021.

Novartis AG Net Income

Novartis AG reported a net profit of approximately 8,100 million U.S. Dollars in 2020, making it one of the top pharmaceutical companies worldwide. The net income grew three-fold to 24,000 million dollars a year later.

Novartis AG Top Drugs, by Revenue

Novartis’ third most-sold pharmaceutical for Gilenya in 2021 was a total of approximately 2,787 million U.S. Dollars worldwide.

Novartis AG Revenue, by Region

This statistic represents revenue for 2017-2021. It is broken down by region. This multinational pharmaceutical company, which is based in Basel (Switzerland), is one of the most important pharmaceutical companies. Total revenue of 51,600 million U.S. dollars in 2021. About 20,197 million U.S. dollars were generated in Europe.

Novartis AG Total Assets

This stat shows the total assets from 2015 to 2021. They rank among the top global pharmaceutical corporations. Total assets were estimated to be 131,795 million U.S. dollars in 2021.

Novartis AG Expenditure, by Type

This statistic displays the expenses from 2018 to 2021. This is the largest pharma company in the world. They spent around 14,886 million U.S. Dollars on sales, general, and administration (SG&A) in 2021.

Recent Developments:


  • Novartis joined a research partnership with GlaxoSmithKline in January to help support scientific research into African genetic diversity.
  • Novartis invested in Credence Medical Systems, an innovator in drug delivery system technology, in January.
  • Novartis, BioNTech, and Pfizer signed an agreement in February for the production of mRNA vaccines.
  • Novartis received the Therapeutic Goods Administration approval in February to manufacture and commercially supply its CAR–T therapies for eligible patients in Australia.
  • Novartis receives FDA Approval for Ligelizumab (QGE031) Breakthrough Therapy Designation for Chronic Spontaneous Urticaria Treatment.
  • Novartis was joined by Enel X in March to promote electric transportation in Italy.
  • Novartis joined MD Anderson and Puma biotechnology in a collaboration with Celcuity Inc for a Phase II clinical trial.
  • Regulatory approval; company obtained EU approval in March for Kesimpta, a medication for adults with relapsing multiple sclerosis.
  • Novartis announced a worldwide research collaboration with Artios Pharma Ltd to identify and validate the next-generation DDR targets for Novartis’ Radioligand Therapies.
  • Novartis announced a collaboration with Kaiku Health Oy to develop digital patient monitoring, management, and treatment for patients suffering from melanoma.
  • Novartis & Roche announced a collaboration in April to execute the technology transfer to make the active pharmaceutical ingredient used to treat rheumatoid arthritis.
  • Novartis was joined by Ada Health in May to help patients with immunological disorders and rare conditions.
  • Novartis and Cellerys, a Zurich startup, entered into a cooperation agreement in June.
  • Novartis and Hewlett Packard Enterprise formed a partnership in June to help advance global health initiatives.
  • Novartis’s Sandoz Division launched ready-to-dilute generic Pemetrexed for the treatment of patient lung cancer. It was available in 11 countries.
  • Novartis bought Arctos Medical, an innovative Swiss gene therapy company, in September.
  • Novartis and Global Heart Hub partnered to combat atherosclerotic cardio disease in October.
  • Novartis reached an agreement with BioNTech in October to help produce the Pfizer BioNTech COVID-19 vaccine.
  • Novartis reached an agreement with Roche to sell 33% Roche bearer stock in a bilateral transaction for US$20,700 million in November.
  • Novartis was joined by Dunad Therapeutics in November to create protein degrading drugs.
  • Novartis revealed its plans to acquire Kedalion Therapeutics in November.
  • Novartis signed an agreement with Gyroscope Therapeutics in the UK, which was acquired by December.

Share This Statistics


Pharmaceutical Industry/Brands Statistics and Facts


Eli Lilly and Company Statistics and Facts